GlassScriptPhysician profile
Kristin Cagle
NPI 1457934093
$4,806.23
in general payments reported to CMS, 2019-2025
28 companies · $1,342 in 2025
The $1,342 reported for 2025 was more than what 97% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $161 · 2022: $1,521 · 2023: $574 · 2024: $1,208 · 2025: $1,342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,124.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,524.61 | 2021-2025 | Briviact, Fintepla |
| Livanova USA, INC. | $759.05 | 2022 | |
| Jazz Pharmaceuticals INC. | $708.33 | 2022-2025 | |
| Eisai INC. | $171.97 | 2021-2023 | |
| Neurelis, INC. | $167.15 | 2022-2025 | Valtoco |
| Catalyst Pharmaceuticals, INC. | $146.50 | 2023-2025 | Fycompa |
| Aucta Pharmaceuticals, INC. | $120.91 | 2024-2025 | Motpoly Xr |
| Sk Life Science, INC. | $116.56 | 2023-2025 | |
| Collegium Pharmaceutical, INC. | $108.79 | 2025 | Jornay Pm |
| Abbvie INC. | $104.45 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $100.42 | 2024-2025 | Daybue |
| Immedica Pharma US, INC. | $99.40 | 2022-2025 | Ztalmy |
| Supernus Pharmaceuticals, INC. | $97.19 | 2021 | |
| Novartis Pharmaceuticals Corporation | $84.04 | 2024-2025 | |
| Upsher-Smith Laboratories LLC | $80.61 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $70.56 | 2023-2024 | Aptiom |
| Otter Pharmaceuticals, LLC | $53.49 | 2025 | Sympazan |
| Azurity Pharmaceuticals, INC. | $52.07 | 2024-2025 | Zonisade |
| Sunovion Pharmaceuticals INC. | $35.52 | 2022 | |
| Sarepta Therapeutics, INC. | $30.71 | 2023 | Elevidys |
| Biogen, INC. | $26.53 | 2024 | Spinraza |
| Ns Pharma, INC. | $25.23 | 2023 | Viltepso |
| Ipsen Biopharmaceuticals, INC | $24.63 | 2025 | Dysport |
| Teva Pharmaceuticals USA, INC. | $23.36 | 2025 | Ajovy |
| Alexion Pharmaceuticals, INC. | $20.76 | 2025 | Koselugo |
| Amneal Pharmaceuticals LLC | $17.94 | 2023 | Lyvispah |
| Medtronic, INC. | $17.86 | 2022 | |
| Aquestive Therapeutics, INC. | $17.59 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristin Cagle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.